This 67 year-old female patient presented with peripheral arterial disease, controlled type II diabetes and a 10 cm2 VLU above her right ankle that had been open for 46 weeks.
Treatment with RESTM introduced healthy skin cells, representing all normal phenotypes and wound healing factors to overcome the dysfunctional cell processes and cellular signalling that had impaired the healing of her wound.
At 13 weeks post-treatment, the patient’s wound had decreased to less than 1cm2 and her pain had been reduced significantly.
Photos courtesy of Dr Paul Hayes, Addenbrookes Cambrdige
A 48-year-old female patient with diabetic foot ulcer of approximately 80cm2
The wound was debrided to pinpoint bleeding and immediately treated with RESTM together with a split thickness skin graft. At 10 days epithelialisation of the wound was observed, with the wound fully healed at 26 weeks.
This case is representative of 44 cases from the Randomized Clinical Trial of autologous skin cell suspension (RESTM) combined with skin grafting for chronic wounds.
RES™ was used to treat this large VLU to ensure earlier definitive closure. The wound was well vascularised and had a good granulation layer but would not close.
RES™ was used to overcome the dysfunctional cell signalling present in the unresponsive hard to heal wound. The multi-phenotype composition of RES™, together with the signalling factors these keratinocytes and fibroblasts produce, replaces dysfunctional cells and restarts the normal healing processes that have stalled within these wounds.